NasdaqCM - Nasdaq Real Time Price USD

Alzamend Neuro, Inc. (ALZN)

Compare
1.1100 -0.1400 (-11.20%)
At close: December 20 at 4:00:03 PM EST
1.1600 +0.05 (+4.50%)
Pre-Market: 5:44:41 AM EST

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Stephan Jackman CEO & Director 443.62k -- 1976
Mr. Milton Charles Ault III Founder & Vice Chairman 8.33k -- 1970
Mr. David J. Katzoff Chief Financial Officer 150k -- 1962
Mr. Henry C. W. Nisser Esq. Executive VP, General Counsel & Director 50k -- 1969
Mr. Kenneth S. Cragun CPA Senior Vice President of Finance -- -- 1961

Alzamend Neuro, Inc.

3480 Peachtree Road NE
Second Floor, Suite 103
Atlanta, GA 30326
United States
844 722 6333 https://www.alzamend.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
4

Description

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Corporate Governance

Alzamend Neuro, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

December 11, 2024 at 9:00 PM UTC

Alzamend Neuro, Inc. Earnings Date

Recent Events

December 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 11, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 15, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 3, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 11, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 31, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 30, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

July 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 3, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

Related Tickers